Verified Clinical Trials launches in Japan to curb duplicates

Verified Clinical Trials (VCT) is now operating in Japan. They teamed up with Medical Revolutions Japan (MRJ) and the Japan Association of Contract Institutes for Clinical Pharmacology (JACIC) to provide subject registry solutions. This change aims to improve Japan’s system for stopping duplicate and professional subjects in clinical trials. The current system has been in place for over 30 years and is now seen as outdated.

The VCT platform is used in about 40 countries. It provides a registry for subjects that spans different sponsors and therapies. It uses biometric authentication to find and prevent duplicate enrollments and protocol violations in all trial phases (Phase I–IV). Its use in Japan comes as worries grow about subject duplication, especially in later trials.

Also Read: Chugai and Gero Join Forces on Aging Disease Therapies

The rollout, backed by MRJ, is a big step in aligning Japan’s clinical trial practices with global standards. VCT helps sponsors protect data and ensure protocol compliance. It does this by allowing real-time screening and ongoing checks of participant eligibility. This initiative shows a deep commitment to better trial quality and regulatory standards in the Asia-Pacific region.